These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33403821)

  • 1. Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial.
    Choi HK; Neogi T; Stamp LK; Terkeltaub R; Dalbeth N
    Arthritis Rheumatol; 2021 May; 73(5):721-724. PubMed ID: 33403821
    [No Abstract]   [Full Text] [Related]  

  • 2. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.
    MacDonald TM; Ford I; Nuki G; Mackenzie IS; De Caterina R; Findlay E; Hallas J; Hawkey CJ; Ralston S; Walters M; Webster J; McMurray J; Perez Ruiz F; Jennings CG;
    BMJ Open; 2014 Jul; 4(7):e005354. PubMed ID: 25011991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
    Alten R; Mischkewitz M; Nitschmann S
    Internist (Berl); 2020 May; 61(5):530-532. PubMed ID: 32130437
    [No Abstract]   [Full Text] [Related]  

  • 4. Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol.
    Pawar A; Desai RJ; Liu J; Kim E; Kim SC
    J Am Heart Assoc; 2021 Apr; 10(7):e020045. PubMed ID: 33764153
    [No Abstract]   [Full Text] [Related]  

  • 5. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
    Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
    Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative cardiovascular risk of allopurinol versus febuxostat in patients with gout: a nation-wide cohort study.
    Kang EH; Choi HK; Shin A; Lee YJ; Lee EB; Song YW; Kim SC
    Rheumatology (Oxford); 2019 Dec; 58(12):2122-2129. PubMed ID: 31098635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular risk in gout - Role of allopurinol?].
    de Jong ICA; van Herwaarden N; Rongen GA; van der Pol KH
    Ned Tijdschr Geneeskd; 2021 Apr; 165():. PubMed ID: 33914423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
    White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
    N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study comparing the safety and efficacy of febuxostat, allopurinol, and benzbromarone in Chinese gout patients: a retrospective cohort study
.
    Zhou Q; Su J; Zhou T; Tian J; Chen X; Zhu J
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):163-168. PubMed ID: 27936522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.
    Wang S
    Pak J Pharm Sci; 2018 Jul; 31(4(Special)):1623-1627. PubMed ID: 30203749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gout: Why compare the effectiveness of suboptimal gout management?
    Dalbeth N; Stamp LK
    Nat Rev Rheumatol; 2015 Sep; 11(9):506-7. PubMed ID: 26150126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of febuxostat in gout.
    Bardin T; Richette P
    Curr Opin Rheumatol; 2019 Mar; 31(2):152-158. PubMed ID: 30601228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
    Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
    J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in gout: some answers, more questions.
    Singh JA
    Arthritis Res Ther; 2010; 12(5):136. PubMed ID: 20959031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is febuxostat associated with higher risk of cardiovascular death than allopurinol in treating gout or asymptomatic hyperuricemia?
    Deng JH; Zhong GW; Zhang JX
    Ann Palliat Med; 2022 Aug; 11(8):2789-2791. PubMed ID: 35948476
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription pattern of urate-lowering therapy in Korean gout patients: data from the national health claims database.
    Kim JW; Kwak SG; Park SH
    Korean J Intern Med; 2018 Jan; 33(1):228-229. PubMed ID: 28823114
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
    Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
    Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.
    Perez-Ruiz F; Chinchilla SP; Atxotegi J; Urionagüena I; Herrero-Beites AM; Aniel-Quiroga MA
    Rheumatol Int; 2015 Nov; 35(11):1857-61. PubMed ID: 26342297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.